Recurrent Melanoma Recruiting Phase 1 Trials for Paclitaxel (DB01229)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02020707Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological CancersTreatment